May 7, 2026

Featuring an interview with Dr Nikhil I Khushalani, including the following topics:

• Overview of nonmelanoma skin cancers (0:00)
• Systemic therapy for nonmelanoma skin cancers (12:11)
• Immune checkpoint inhibitors for special patient populations (20:30)
• Hedgehog inhibitors for basal cell carcinoma (32:14)
• New developments...

May 2, 2026

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics:

• Role of circulating tumor DNA (ctDNA) testing in the escalation of treatment for Stage II and deescalation for Stage III colon cancer (0:00)
• Impact of timing on the clinical...

Apr 30, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 2: Future Directions in the Use of Oral SERDs for HR-Positive, HER2-Negative BC — Erica Mayer, MD, MPH, FASCO

CME information and select...

Apr 30, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 1: Appropriate Identification of Candidates for and Practical Implementation of Oral Selective Estrogen Receptor Degraders (SERDs) for Progressive HR-Positive,...

Apr 30, 2026

Featuring perspectives from Dr Aditya Bardia and Dr Erica Mayer, including the following topics:

• Introduction: How Selective Estrogen Receptor Degraders (SERDs) Work (0:00)
• Second-Line Treatment for Metastatic Breast Cancer (16:01)
• First-Line Therapy for Metastatic Disease (33:19)
• Adjuvant Therapy (35:26)
• Toxicity,...